. Author manuscript; available in PMC: 2021 May 1.

Published in final edited form as: J Geriatr Oncol. 2019 Nov 6;11(4):557–565. doi: 10.1016/j.jgo.2019.10.007

Table 2.

Local ablative therapies in patients with localized HCC.

	Study	Survival	Survival in Older adults
Radiofrequency ablation (RFA)	Cucchetti et al⁵⁸	3-year OS: 76%	n/a
	Mirici-Cappa et al¹⁹	mOS: 42 mo	n/a
	SURF trial⁶²	3-year RFS: surgery 49.8% vs RFA 47.7% (p=0.793)	n/a

Transarterial chemoembolization (TACE)	Llovet et al⁶³	2-year survival: 63% vs 27% control (p=0.009)	n/a
	Lo et al⁶⁵	3-year survival: 26% vs 3% control (p=0.002)	n/a
	Zhou et al⁹⁷	n/a	mOS: 21 mo (70.4 +/− 4.6 years)
	Mirici-Cappa et al¹⁹	n/a	mOS: 26 mo (74.6 +/− 3.9 years)

Selective internal radiation therapy (SIRT)	SARAH study⁶⁷	mOS: 8.0 mo vs 9.9 mo sorafenib (p=0.18)	n/a
Selective internal radiation therapy (SIRT)	Golfieri et al⁶⁸	n/a	mOS: 14.5 mo older vs 12.8 mo younger (p=0.942) (74.3 years ((70–87))

Stereotactic body radiotherapy (SBRT)	Rajyaguru et al⁹⁸	5-year OS: 29.8% RFA vs 19.3% SBRT (p<0.001)	n/a
Stereotactic body radiotherapy (SBRT)	Teraoka et al⁶⁹	n/a	mOS: 52 mo vs NR younger (p=0.27) (79 years (75–93))

OS = overall survival, mOS = median overall survival, mo = months, vs = versus, NR = not reached, n/a = not available